Wat is de prijs voor Marizyme, Inc. (MRZM)

Het prijs van Marizyme, Inc. (MRZM) is $0.0003

Wat is de marktkapitalisatie voor Marizyme, Inc. (MRZM)

Marktkapitalisatie voorMarizyme, Inc. (MRZM) is $39.54K

Marizyme, Inc. (MRZM) Uitstaande Aandelen

Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.

Jaar	Uitstaande aandelen	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Uitstaande aandelen

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Uitstaande aandelen	Verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	0.00	-	BE

Bedrijf

Uitstaande aandelen

Verschil

Land